Equity Profile

GRAL

GRAIL, Inc.

Health CareBiotechnology$3.1B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through advanced blood tests....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and investors will be keen to see if GRAIL continues its trend of beating estimates.

N/A

Revenue Growth

While specific revenue estimates are not available, any indication of growth in sales will be important for assessing market demand for GRAIL's products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through advanced blood tests. As part of the health care sector, its innovations could significantly impact cancer treatment and patient outcomes, making it a key player in the fight against cancer.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In Q1 2026, GRAIL reported an EPS of -$2.29, beating estimates by 23.67%. However, the stock fell 2.26% the following day, indicating some investor disappointment despite the positive surprise.

Management Promises & Guidance

Continued focus on product development and market expansion.
Commitment to improving operational efficiencies.
Plans to enhance customer outreach and education regarding early cancer detection.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about GRAIL's upcoming earnings, especially given its history of beating EPS estimates. However, the lack of revenue guidance raises concerns about future growth.

Bull Case

If GRAIL can demonstrate strong revenue growth alongside continued EPS surprises, it may attract more investor interest and drive the stock price higher.

Bear Case

Conversely, if the company fails to show meaningful revenue growth or if the EPS surprise is not enough to offset concerns about future profitability, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue growth for GRAIL's early cancer detection tests?

Revenue growth will be crucial for assessing market demand and the company's ability to scale its operations.

Will GRAIL maintain its trend of beating EPS estimates this quarter?

Continuing to beat EPS estimates could bolster investor confidence and support the stock price.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for GRAIL's products to capture market share in early cancer detection, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

GRAIL has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing a larger move than historical averages, suggesting that investors are expecting significant news.

Recent trends in the biotechnology sector show increasing demand for innovative health care solutions.

Key Risk

If GRAIL's revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will hinge on GRAIL's ability to show both profitability and growth, which are critical for investor sentiment.

Bull Confirmed If

Demonstrating revenue growth of at least 15% year-over-year would confirm the bull case.

Bear Confirmed If

Failing to beat the previous EPS surprise of -$2.29 could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move, reflecting uncertainty about the earnings outcome.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations and raises guidance, history suggests the stock could rise by an average of 1.90% the next day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess.

Miss

If GRAIL misses expectations, history suggests a potential decline of around 5.31% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on partnerships or collaborations that could enhance market reach.
2Details on customer feedback regarding the early cancer detection tests.
3Insights into operational efficiencies that could improve margins.
4Management's outlook on the competitive landscape in the biotechnology sector.
5Any commentary on regulatory developments affecting product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through advanced blood tests....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability, and investors will be keen to see if GRAIL continues its trend of beating estimates.

N/A

Revenue Growth

While specific revenue estimates are not available, any indication of growth in sales will be important for assessing market demand for GRAIL's products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GRAL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In Q1 2026, GRAIL reported an EPS of -$2.29, beating estimates by 23.67%. However, the stock fell 2.26% the following day, indicating some investor disappointment despite the positive surprise.

Management Promises & Guidance

Continued focus on product development and market expansion.
Commitment to improving operational efficiencies.
Plans to enhance customer outreach and education regarding early cancer detection.

Expectations

Wall Street Expectations

Bull Case

If GRAIL can demonstrate strong revenue growth alongside continued EPS surprises, it may attract more investor interest and drive the stock price higher.

Bear Case

Conversely, if the company fails to show meaningful revenue growth or if the EPS surprise is not enough to offset concerns about future profitability, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue growth for GRAIL's early cancer detection tests?

Revenue growth will be crucial for assessing market demand and the company's ability to scale its operations.

Will GRAIL maintain its trend of beating EPS estimates this quarter?

Continuing to beat EPS estimates could bolster investor confidence and support the stock price.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for GRAIL's products to capture market share in early cancer detection, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

GRAIL has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing a larger move than historical averages, suggesting that investors are expecting significant news.

Recent trends in the biotechnology sector show increasing demand for innovative health care solutions.

Key Risk

If GRAIL's revenue growth exceeds expectations, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will hinge on GRAIL's ability to show both profitability and growth, which are critical for investor sentiment.

Bull Confirmed If

Demonstrating revenue growth of at least 15% year-over-year would confirm the bull case.

Bear Confirmed If

Failing to beat the previous EPS surprise of -$2.29 could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±18.37%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move, reflecting uncertainty about the earnings outcome.

Options are pricing ±18.4% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

69.2%

Calls (138K)P/C Ratio: 1.60Puts (89K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations and raises guidance, history suggests the stock could rise by an average of 1.90% the next day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess.

Miss

If GRAIL misses expectations, history suggests a potential decline of around 5.31% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on partnerships or collaborations that could enhance market reach.
2Details on customer feedback regarding the early cancer detection tests.
3Insights into operational efficiencies that could improve margins.
4Management's outlook on the competitive landscape in the biotechnology sector.
5Any commentary on regulatory developments affecting product approvals.